M&A activity in the healthcare and life sciences space reached Covid-era lows in the first quarter due to concerns about debt and credit markets, lower valuations, and headwinds from rising interest rates and labor shortages persist. Nonetheless, industry experts are resoundingly optimistic in their forecasts of a bounce-back for the sector as private equity investors begin to channel their stockpiles of capital back into middle-market healthcare providers.
To read the entire story, you must be logged in.
Please log in now or register with us.
